✦ LIBER ✦

A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C

✍ Scribed by M Rumi; E Del Ninno; M L Parravicini; R Romeo; R Soffredini; M F Donato; J Wilber; A Russo; M Colombo

Publisher: John Wiley and Sons
Year: 1996
Tongue: English
Weight: 202 KB
Volume: 24
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.510240609

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized trial comparing three differe

Randomized trial comparing three different regimens of interferon alfa 2a in chronic hepatitis C

✍ M Angelico 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 2 views

small numbers of HCC cells may be released into the man research review committee. Informed consent had been obtained from the patients involved. circulation, be it spontaneously or induced by surgical The results show that albumin mRNA can be demanipulation. Based on their findings, the authors su

Short-term interferon-alfa therapy for a

Short-term interferon-alfa therapy for acute hepatitis C: A randomized controlled trial

✍ Hideyuki Nomura; Suketo Sou; Hironori Tanimoto; Takashi Nagahama; Yoichi Kimura; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 1 views

Lymphoblastoid interferon alfa-n1 improv

Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: Results of an international randomized controlled trial

✍ Geoffrey C. Farrell; Bruce R. Bacon; Robert D. Goldin 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 2 views

The aim of this study was to compare the short-term and long-term efficacy and safety of lymphoblastoid interferon with a recombinant interferon alfa (IFN-␣) in a 24-week treatment course for chronic hepatitis C. One thousand seventy-one patients with chronic hepatitis C were randomized to receive l

High doses of recombinant α-interferon o

High doses of recombinant α-interferon or γ-interferon for chronic hepatitis C: A randomized, controlled trial

✍ Federico Sáez-royuela; Juan Carlos Porres; Alberto Moreno; Inmaculada Castillo; 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 438 KB

Chronic hepatitis C is often a progressive liver disease for which there is no satisfactory treatment. We studied the efficacy of recombinant a-interferon or y-interferon in the treatment of this disease in comparison with a control group. Thirty patients were randomly assigned to three groups. Ten

Response to higher doses of interferon a

Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial

✍ K L Lindsay; G L Davis; E R Schiff; H C Bodenheimer; L A Balart; J L Dienstag; R 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

JANICE ALBRECHT, 12 AND THE HEPATITIS INTERVENTIONAL THERAPY GROUP\* with continued therapy at that dose; however, a propor-To evaluate response rates to 3, 5, or 10 million units tion of patients who do not respond to 12 weeks of treat-(MU) of interferon alfa-2b, given thrice weekly, and to ment wi

Randomized controlled trial of pegylated

Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6

✍ Khoa D. Lam; Huy N. Trinh; Son T. Do; Thuan T. Nguyen; Ruel T. Garcia; Tuan Nguy 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 246 KB 👁 2 views

Hepatitis C virus (HCV) genotype is an important criteria in determining duration of therapy and predictor of sustained virologic response (SVR) to pegylated interferon (PEG IFN) and ribavirin (RBV) therapy. Optimal duration of therapy for patients with HCV genotype 6 is not known. We conducted a mu